Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Zydus Lifesciences

NSE: ZYDUSLIFEPharmaceuticals

Share price

₹1,112.00

-3.56% close of 8 Oct 2026

Market cap ₹1.12L CrP/E 23.1

Business score

How strong the business is, in one number. The parts behind it are in Pro.

70

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹1.12L Cr

P/E ratio

23.1

P/B ratio

4.1

ROCE

21.1%

ROE

21.3%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,215.0052-week low ₹860.60

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 21.1% over the past year, and 14.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 21.0% to 29.3% over the last four years.

Whether it grew faster than its sector

It grew 14.4% a year against a sector median of 13.1% — 1.3 percentage points faster.

Room to re-rate, or risk of de-rating

At 23.1× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 21.2×, the 71st percentile of its own range.

Whether growth justifies the valuation

Priced at 0.7 times its growth rate, on earnings growth of 32%.

Profit growthPrice per ₹1 profitPer 1% growth
Zydus Lifesciences — this one32%/yr23.1×₹0.72
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Laurus Labs Limited4%/yr98.6×₹24.7
Cipla10%/yr29.6×₹3.0

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 36 of 130 on returns, 46 of 127 on growth, 20 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 21.1% on capital, ahead of 72% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹16919 crore of cash from the business, spent ₹7218 crore on plant and equipment, and returned ₹724 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 90 arrived as cash. Its cash comes back faster than it used to: it went from being waiting 19 days for its cash to paid 40 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Sales rose 22%, ahead of the high-teens guided, but net profit fell 35% as margin narrowed to 24.1%

Announced 11 Aug 2026 · Consolidated · Unaudited

Revenue

₹8,017 Cr

Revenue vs last year

+22.0%

Revenue vs last quarter

+5.7%

Net profit

₹990 Cr

Profit vs last year

-34.9%

Profit vs last quarter

-26.2%

Net margin

12.4%

EPS

₹9.35

Earnings call transcript · 11 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹1.12L Cr
Prev close
₹1,112.00
52w High
₹1,232
52w Low
₹836
Enterprise value
₹1.18L Cr
Beta
0.8
Price CAGR 1y
17.0%
Price CAGR 3y
24.0%
Price CAGR 5y
16.0%
Price CAGR 10y
12.0%

Ratios

Return on assets
10.1%
PEG ratio
0.7
P/E ratio
23.1
P/B ratio
4.1
EV / EBITDA
14.1
Industry P/E
38.0
ROCE
21.1%
ROCE 5y average
19.0%
ROE
21.3%
Debt / Equity
0.5
Interest coverage
16.1
Dividend yield
0.1%
ROE 3y average
21.0%
ROE last year
21.0%

Annual P&L

Annual revenue
₹27,148 Cr
Annual profit
₹5,124 Cr
Operating margin
31.0%
Net profit margin
18.9%
EBITDA margin
31.2%
Sales growth 3y
16.3%
Sales growth 5y
12.4%
Profit growth 3y
32.0%
Profit growth 5y
19.0%
EPS
₹50.1
Sales growth TTM
21.0%
Profit growth TTM
5.0%
Dividend payout
2.0%

Quarter P&L

Sales latest quarter
₹8,017 Cr
Profit latest quarter
₹990 Cr
YoY quarterly sales growth
22.0%
YoY quarterly profit growth
-34.9%
OPM latest quarter
24.1%

Balance Sheet

Book Value
₹268
Face Value
₹1.0
Total debt
₹12,496 Cr
Total cash
₹1,417 Cr
Borrowings
₹12,496 Cr
Reserves / Equity
267.4

Cash Flow

Operating cash flow
₹2,117 Cr
Free cash flow
-₹530 Cr
FCF yield
-0.9%
Net cash flow
₹28 Cr

Shareholding

Promoter holding
75.0%
FII holding
7.0%
DII holding
11.3%
Public holding
6.7%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,745.0033.04,18,6840.902,901.26.015,299.910.520.5
Divi's Lab.9,357.0083.42,48,3990.31902.065.53,080.027.822.0
Torrent Pharma.4,598.0078.41,74,8930.81566.05.84,921.054.915.2
Zydus Lifesci.1,109.6522.81,10,6880.09990.2-35.18,017.022.021.1
Laurus Labs2,005.0099.11,08,3330.10362.1125.52,026.329.117.8
Cipla1,305.0029.41,05,4270.97785.6-39.27,119.32.315.5
Dr Reddy's Labs1,175.0030.598,0750.67435.6-68.78,099.8-5.513.0
Median417.0033.82,1130.0713.529.5164.018.415.0

Competes with: Aarey Drugs & Pharmaceuticals Limited, Aarti Drugs Limited, Aarti Pharmalabs Limited, Abbott India Limited, Acutaas Chemicals Limited, Ajanta Pharma Limited, Akums Drugs and Pharmaceuticals Limited, Albert David Limited, Alembic Pharmaceuticals Limited, Alivus Life Sciences Limited, Alkem Laboratories Limited, Alpa Laboratories Limited, Amanta Healthcare Limited, Ambalal Sarabhai Enterprises Limited, Amrutanjan Health Care Limited, Anlon Healthcare Limited, Anuh Pharma Limited, AstraZeneca Pharma India Limited, Aurobindo Pharma, BALAXI PHARMACEUTICALS LIMITED, Bafna Pharmaceuticals Limited, Bajaj Healthcare Limited, Bal Pharma Limited, Beta Drugs Limited, Bharat Parenterals Limited, Biocon, Biofil Chemicals & Pharmaceuticals Limited, Bliss GVS Pharma Limited, Blue Jet Healthcare Limited, Brooks Laboratories Limited, CORONA Remedies Limited, Caplin Point Laboratories Limited, Cipla, Cohance Lifesciences Limited, Concord Biotech Limited, Dishman Carbogen Amcis Limited, Divi's Laboratories, Dr Reddy's Laboratories, Emcure Pharmaceuticals Limited, Eris Lifesciences Limited, FDC Limited, Fermenta Biotech Limited, Fredun Pharmaceuticals Limited, Gland Pharma Limited, GlaxoSmithKline Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Granules India Limited, Gufic Biosciences Limited, Gujarat Themis Biosyn Limited, HALEOS LABS LIMITED, Hester Biosciences Limited, Hikal Limited, IOL Chemicals and Pharmaceuticals Limited, IPCA Laboratories Limited, Ind-Swift Laboratories Limited, Indoco Remedies Limited, Innova Captab Limited, JB Chemicals & Pharmaceuticals Limited, Jagsonpal Pharmaceuticals Limited, Jeena Sikho Lifecare Limited, Jenburkt Pharmaceuticals Limited, Jubilant Pharmova Limited, Kilitch Drugs (India) Limited, Kopran Limited, Krebs Biochemicals and Industries Limited, Kwality Pharmaceuticals Limited, Lasa Supergenerics Limited, Laurus Labs Limited, Lincoln Pharmaceuticals Limited, Lupin, Lyka Labs Limited, Makers Laboratories Limited, Mangalam Drugs And Organics Limited, Mankind Pharma Limited, Marksans Pharma Limited, Medi Caps Limited, Medicamen Biotech Limited, Medico Remedies Limited, Morepen Laboratories Limited, NGL Fine-Chem Limited, Natco Pharma Limited, Natural Capsules Limited, Nectar Lifesciences Limited, Neuland Laboratories Limited, Novartis India Limited, ORTIN GLOBAL LIMITED, Onesource Specialty Pharma Limited, Orchid Pharma Limited, Panacea Biotec Limited, Par Drugs And Chemicals Limited, Parnax Lab Limited, Pfizer Limited, Piramal Pharma Limited, Procter & Gamble Health Limited, RPG Life Sciences Limited, Rubicon Research Limited, SMS Pharmaceuticals Limited, Sai Life Sciences Limited, Sai Parenterals Limited, Sakar Healthcare Limited, Sanofi Consumer Healthcare India Limited, Sanofi India Limited, Senores Pharmaceuticals Limited, Shilpa Medicare Limited, Shree Ganesh Remedies Limited, Shukra Pharmaceuticals Limited, Sigachi Industries Limited, Solara Active Pharma Sciences Limited, Strides Pharma Science Limited, Sudeep Pharma Limited, Sun Pharma Advanced Research Company Limited, Sun Pharmaceutical, Sunil Healthcare Limited, Supriya Lifescience Limited, Symbiotec Pharmalab Limited, Syncom Formulations (India) Limited, Themis Medicare Limited, Torrent Pharmaceuticals, Unichem Laboratories Limited, Vaishali Pharma Limited, Valiant Laboratories Limited, Venus Remedies Limited, Vineet Laboratories Limited, Vivimed Labs Limited, Viyash Scientific Limited, Wanbury Limited, Windlas Biotech Limited, Wockhardt Limited, Zim Laboratories Limited, Zota Health Care LImited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales5,1404,3694,5055,5346,2085,2375,2696,5286,5746,1236,8657,5878,017
Expenses3,6343,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,0336,088
Material Cost1,1641,2191,3271,2161,3471,251
Change in Inventories-40-88-226-232-343-301
Purchases of Stock-in-Trade5736585898529721,289
Employee Cost9711,0051,0341,1401,2391,368
Other Expenses1,7341,6911,3832,0721,8182,480
Operating Profit1,5051,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,5541,929
OPM %29262429342826333233263424
Other Income215360160636857-1391557526-26388
Exceptional items (within Other Income)-2200-34-85-398-18
Interest18920353225327785101130123156
Depreciation180184195205215234229238238302360508555
Profit before tax1,3281,0069471,5501,9001,2711,1841,6721,9211,6871,3531,6601,307
Tax %16222321232915252327291927
Net Profit1,1348037901,2461,4829201,0261,2441,5211,2391,0231,341990
EPS in Rs117.917.8012149.061012151310139.42
Diluted EPS in Rs12151310139.35

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales8,6519,4279,37611,90513,16614,25315,10215,26517,23719,54723,24227,14828,592
Expenses6,8967,0957,4749,07410,17411,45511,75811,92313,37814,16316,18318,67320,276
Material Cost4,3735,110
Change in Inventories-185-888
Purchases of Stock-in-Trade2,1503,071
Employee Cost3,6814,418
Other Expenses6,1646,963
Operating Profit1,7562,3321,9022,8312,9912,7983,3443,3423,8605,3847,0588,4758,316
OPM %20252024232022222228303129
Other Income45112127111183-264-1712,581-42229350-7-74
Exceptional items (within Other Income)-220-517
Interest6853459119434216412713081166439510
Depreciation2872923735395996967257137237649161,4081,725
Profit before tax1,4462,0991,6122,3122,3821,4952,2855,0842,5854,8326,0276,6216,007
Tax %188824222161023202324
Net Profit1,1881,9641,5171,8101,8991,2042,1854,6182,0923,9734,6735,1244,593
EPS in Rs11191517181121441938455045
Diluted EPS in Rs4550
Dividend Payout %211722201930176318242

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
11%
5 years
12%
3 years
16%
TTM
21%

Compounded profit growth

10 years
11%
5 years
19%
3 years
32%
TTM
5%

Stock price CAGR

10 years
12%
5 years
16%
3 years
24%
1 year
17%

Return on equity

10 years
20%
5 years
21%
3 years
21%
Last year
21%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital102102102102102102102102101101101101
Reserves4,1495,5976,8588,64210,28410,27312,89016,89717,41519,72923,85327,011
Borrowings2,6512,4425,2075,4077,8997,9864,5844,2211,1958043,21312,496
Other Liabilities2,1442,2082,9373,6324,9455,1156,1896,4216,8518,2019,52311,065
Minority Interest2,4052,471
Total Liabilities9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68950,673
Fixed Assets3,3523,7485,7556,48312,16412,23012,13312,25311,52112,36813,13424,106
CWIP7989511,5431,5278377427836611,2012,4232,6923,698
Investments1544164357466747658303,2881,5471,2206,4127,540
Other Assets4,7435,2357,3719,0289,5569,74010,01911,43911,29412,82214,45115,328
Total Assets9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68950,673

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity9941,8941,3129191,2822,5053,2932,1042,6893,2286,7812,117
Cash from Investing Activity-465-860-2,872-974-3,977-1,012-8351,1371,178-1,492-8,363-7,895
Cash from Financing Activity-351-9352,316521,885-1,094-2,549-868-4,400-1,8101,9955,807
Net Cash Flow17899756-3-811399-902,373-534-7541428
Free Cash Flow498936-1,623-1162361,6172,4461,0501,6972,3455,139-530

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6768899811094768094976473
Inventory Days175158193211208207227245197202227282
Days Payable125154165167149151155141123125131142
Cash Conversion Cycle11871116142169150148184168175160212
Working Capital Days6-1-341710-19-61970883-40
ROCE %232816181511141315222421

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Sep 2026
Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters757575757575757575757575
FIIs4.995.725.597.527.537.317.137.347.066.956.897.05
DIIs131313111111111111111111
Government0.070.070.070.050.050.050.0400000
Public6.996.666.816.856.856.696.746.816.866.866.836.66
No. of Shareholders3,06,4952,94,3243,36,3093,70,8633,65,3563,71,6193,86,1273,96,1054,03,2664,18,3143,99,2513,82,067

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +11.8% (₹994.45 → ₹1,112.00)Brick size ₹31.83 (fixed)Bricks 18
₹900₹1,000₹1,112Jan '26May '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹1,112.00 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

5,303inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

90,55,370inr

2026-03-31

News

News and filings about Zydus Lifesciences. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active Pharmaceutical Ingredient (API)
  • Excipients
  • Key Starting Material (KSM)
  • Pharmaceutical Intermediates
  • Solvents

Buys from

Sells to

  • China Medical System Holdings (CMS) · licensed novel molecule (out-licensing)
  • Emerging Markets (APAC, MEA, LatAm) · formulations
  • Europe (France, Spain, UK) · formulations

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE010B01027

Business segments

  • Pharmaceuticals · 83%
  • Consumer products · 15%
  • Medical technologies · 3%

Plants

  • Ambernath API Plant
  • Ankleshwar API Plant
  • Baddi Formulations Plant
  • Changodar Biologics & Vaccine Technology Centre
  • Changodar Topical & Transdermal Plant
  • Dabhasa API Plant · Dabhasa, Gujarat
  • Jarod/Waghodia Injectables Plant
  • Matoda Pharma SEZ Plant
  • Moraiya Formulations & Vaccines Plant
  • Ponda Formulations Plant
  • Sikkim Plant · Sikkim, Sikkim

News impact

Big market events that reach Zydus Lifesciences, and how the effect spreads.

Who it hits first

  • Sun Pharmaceutical, India's biggest drugmaker by market value, plans to raise Rs 10,000 crore by selling rupee bonds maturing in two, three and four years.
  • The money will refinance borrowings tied to its Organon deal, swapping old deal loans for new bonds rather than funding new factories or drugs.
  • Existing Sun Pharma shareholders face mild pressure from higher interest costs and extra bond supply, partly offset by longer, possibly cheaper maturities.

Who may gain

  • Bond buyers and mutual funds gain fresh, highly rated Sun Pharma paper across 2-4 year maturities.
  • The banks and arrangers running the Rs 10,000 crore sale earn underwriting fees.
  • Long-term Sun Pharma holders could benefit if the new bonds carry lower rates than the old deal debt.

Along the supply chain

Downstream

No downstream effect — Sun Pharma sells finished medicines, and a bond refinancing does not change drug prices, chemist stocks or patient demand.

Upstream

No direct supply-chain link — Divi's Laboratories and other ingredient suppliers to Sun Pharma keep the same orders, since refinancing changes lenders, not production.

Where demand moves

Business

No new drug demand is created — hospitals, chemists and patients buy the same medicines; the only business flow is Sun Pharma swapping one lender for another.

Capital

About Rs 10,000 crore of investor money flows into new Sun Pharma bonds while the repaid Organon deal loans release bank capital for other borrowers, and Sun Pharma shares may see mild selling as leverage headlines weigh.

How it spreads across sectors

Healthcare

Neutral for drug peers — a single company's refinancing moves no industry sales or prices, so rivals from Cipla to Lupin should trade flat.

IT Services

No spillover — the 'Rupee Cascade' keyword fired only because the bonds are rupee-denominated, not because the currency moved, so export-earning sectors see no chain.

A pattern seen before

Cascade chain

Pattern name

Rupee Cascade

Patterns

  • Rupee Cascade

Sectors queried

  • IT Services
  • Oil & Gas
  • Pharma

When it plays out

Immediate

Sun Pharma shares drift mildly on the leverage headline while bond arrangers sound out investors for the 2-4 year tranches.

Medium term

Higher interest costs show up in quarterly results; if rates fell, refinancing savings support earnings instead.

Short term

Bond pricing and demand decide the verdict — a well-bought issue calms equity, a weak one extends the drag.

Who it hits first

  • Anupam Rasayan, a maker of specialty chemicals, has finished buying a controlling 48.2% of Bliss GVS Pharma, a drug maker, for Rs1,750 crore at Rs299 per share.
  • Bliss GVS shareholders who sold get cash at the deal price, and the stock should trade near Rs299 while the open offer settles.
  • Anupam shareholders now own a pharma business too, but the company spent a large sum and takes on more debt and integration work.

Who may gain

  • Bliss GVS Pharma selling shareholders receiving Rs299 per share
  • Bliss GVS Pharma minority holders if the new owner invests and grows the drug business
  • Advisers and brokers who earned fees on the Rs1,750 crore deal and open offer

Along the supply chain

Downstream

UPL, which buys from Anupam Rasayan, sees no change in supply or price from this ownership move, and Bliss GVS has no listed customers in the pack, so downstream flow is flat.

Upstream

Valiant Organics, which supplies materials to Anupam Rasayan, gets no new orders from this share deal — Anupam's factories run as before, so upstream demand is unchanged.

Where demand moves

Business

No new customer demand is created — the same chemicals and drugs are made and sold; only the owner of Bliss shares changes, so business demand flow is flat.

Capital

About Rs1,750 crore of capital flows from Anupam Rasayan to Bliss sellers through the share purchase, open offer, and market top-up, lifting near-term trading in both stocks.

How it spreads across sectors

Chemicals

Neutral — Anupam's cash exit for a pharma asset does not change chemical demand or prices for peers.

Healthcare

Mildly positive mood — a completed Rs299 control price can support small-drug-maker valuations, but no orders move.

When it plays out

Immediate

In 1–7 days both stocks trade on deal arithmetic, with Bliss near Rs299 and Anupam weighed by funding cost; Bliss ASM stage 4 curbs may mute moves.

Medium term

In 1–6 months Anupam must show Bliss earnings adding to group profit; if integration works the deal looks smart, if not the debt load drags.

Short term

In 1–4 weeks the open offer settlement and Anupam's funding details set the tone, with focus on debt taken and pledge levels.

Who it hits first

  • Zydus Lifesciences, the Ahmedabad-based drug maker, had its New Jersey site's drug-safety monitoring system inspected by the US Food and Drug Administration from September 22 to 25.
  • The inspection closed with nil (zero) observations, meaning the inspectors found no problems needing corrective action.
  • This removes a near-term regulatory worry for Zydus's US business but does not by itself create new sales.

Who may gain

  • Zydus Lifesciences — lower US regulatory risk and steadier sentiment for its existing US drug sales.
  • Zydus shareholders — reduced overhang of a warning letter or import restriction at this New Jersey site.

Along the supply chain

Downstream

US distributors, pharmacies and patients see continued supply confidence, but no price or volume shift — this clearance does not approve a new drug.

Upstream

Ingredient, packaging and service suppliers to Zydus see no direct order change — a clean safety-system inspection keeps existing production running rather than adding new volume.

Where demand moves

Business

No new purchase orders flow from this clearance — it is a compliance pass, not a contract win — but it protects Zydus's existing US drug sales from disruption.

Capital

Investors are likely to give Zydus a small relief premium as US regulatory risk falls, with little fresh money moving into rival drug stocks on this news alone.

How it spreads across sectors

Healthcare

Mild positive sentiment for Indian drug exporters on clean USFDA news, but no sector-wide earnings change since the clearance is specific to one Zydus site.

When it plays out

Immediate

1-7 days: Zydus shares firm modestly on relief; rival drug stocks barely move.

Medium term

1-6 months: no lasting uplift unless followed by new US approvals or launches linked to the site.

Short term

1-4 weeks: focus shifts back to Zydus's US pipeline and pricing; the inspection fades as a price driver.

Who it hits first

  • Blue Cloud, a small software firm, said its US arm won a Rs 147 crore fixed-fee order from IBM Cloud to run AI computer systems in the US, and its penny stock jumped over 17%.
  • The listed Blue Cloud shares are not in our data table, so no signal is made for the winner itself; the four similarly named firms below are different businesses.

Who may gain

  • Blue Cloud shareholders, who saw the stock jump over 17% on the IBM order
  • The US subsidiary team that will execute the Rs 147 crore AI work

Along the supply chain

Downstream

Downstream is IBM Cloud in the US, which receives the AI infrastructure work from Blue Cloud's US arm.

Upstream

No upstream link in the pack — server and chip vendors to Blue Cloud are not named, so no supplier call is made.

Where demand moves

Business

Real business flows to Blue Cloud's US arm — Rs 147 crore of AI infrastructure services for IBM Cloud in the US.

Capital

Trading money chased the Blue Cloud penny stock on the news, up over 17%, while the similarly named Blue Star, Blue Dart, Blue Coast and Blue Jet saw no such inflow.

How it spreads across sectors

Information Technology

Company-specific lift only — Blue Cloud gains the work while other software firms see no spillover; no govt-capex chain as this is IT services, not building work.

A pattern seen before

Cascade chain

Pattern name

Govt Capex Cascade

Patterns

  • Govt Capex Cascade

Sectors queried

  • Banking
  • Capital Goods
  • Cement
  • Infrastructure
  • Steel

When it plays out

Immediate

Blue Cloud stock stays volatile over 1-7 days as traders track the Rs 147 crore execution.

Medium term

Over 1-6 months, the stock rests on delivery and whether more IBM work arrives; wrong-name peers stay flat.

Short term

Over 1-4 weeks, price follows proof of work starting and talk of further IBM orders.

23 Sept, 10:54 IST · Market event · high impact

US FDA clears Glenmark's Goa unit with VAI status

The US FDA cleared Glenmark's Goa drug factory with a mostly-clean VAI report, protecting its American sales and shares, while rival drugmakers and suppliers see no real change.

Healthcare

Who it hits first

  • Glenmark Pharmaceuticals, a Mumbai drugmaker selling in the US, got a VAI result (a mostly-clean report card asking for voluntary fixes) from the US FDA for its Goa factory, inspected June 22-30.
  • The clearance removes the fear of an import ban, so medicines made in Goa can keep shipping to America.
  • Rival drugmakers and Glenmark's raw-material suppliers see no direct change from this single-factory result.

Who may gain

  • Glenmark: its Goa plant keeps exporting to the US without an import alert.
  • US buyers and patients: steady supply of Glenmark medicines from Goa.
  • Glenmark shareholders: a regulatory overhang lifts, supporting the share price.

Along the supply chain

Downstream

Downstream, US distributors and pharmacies continue receiving Goa-made drugs without disruption; the pack lists no customer of Glenmark to name further.

Upstream

Upstream, Glenmark's listed suppliers (Alivus, Concord Bio, Sakar and others) keep their existing Goa-linked orders, but a clearance creates no new ingredient demand.

Where demand moves

Business

Real business is protected, not added: Goa-made medicines keep flowing to US distributors and pharmacies, preserving existing export revenue; no rival gains or loses orders from this.

Capital

Capital relief trade: Glenmark shares should firm as the import-alert risk fades, while peer pharma stocks see only faint sympathy flows.

How it spreads across sectors

Healthcare

Mild relief tone: one fewer FDA overhang steadies sentiment for US-exposed drugmakers, but sales move nowhere.

When it plays out

Immediate

Glenmark shares firm as the VAI outcome circulates and import-alert fears unwind.

Medium term

Sustained US shipments and new approvals from the Goa site convert relief into revenue.

Short term

Management commentary on the observations and any remediation timeline sets the next move.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

24 Jul 2026unspecified₹1
25 Jul 2025unspecified₹11
26 Jul 2024unspecified₹3
28 Jul 2023unspecified₹6
28 Jul 2022unspecified₹2.5
28 Jul 2021unspecified₹3.5
23 Mar 2020interim₹3.5
25 Jul 2019unspecified₹3.5

Splits, bonuses & buybacks

  • daily-prices repair: 14 rows from NSE's archive (replace 6, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
24 Aug 2026Prashant Babubhai Patel · Promoter GroupBUY32,577—

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.